ACB1801 enhances tumor immunogenicity by targeting glycolysis/ferroptosis vulnerability and activating STAT1-signaling to overcome anti-PD-1 resistance in MSS colorectal cancer

The study demonstrates that the harmine derivative ACB1801 overcomes anti-PD-1 resistance in microsatellite stable colorectal cancer by activating STAT1 signaling to suppress glycolysis, promote ferroptosis, and enhance tumor immunogenicity, thereby significantly improving therapeutic efficacy through increased CD8+ T cell infiltration.

The Gist

The Big Problem: The "Fortress" That Won't Open

Imagine colorectal cancer as a highly fortified castle. In some types of cancer (called "MSI-H"), the castle walls are crumbling, and the body's immune system (the "army") can easily see the enemy and attack.

However, most colorectal cancers are MSS (Microsatellite Stable). These are like impenetrable fortresses. They have two main defenses:

1. Camouflage: The cancer cells wear a "disguise" (low MHC-I) so the immune army doesn't recognize them as enemies.
2. The Moat: The area around the castle (the Tumor Microenvironment) is filled with "fog" (lactate and bad chemicals) that confuses the immune soldiers, and it's guarded by "traitors" (Regulatory T-cells) who tell the good soldiers to stand down.

Doctors try to use a key called Anti-PD-1 therapy to unlock the immune system's brakes. But for MSS cancer, this key often doesn't work because the castle is too well-hidden and the moat is too toxic. The immune army just sits outside, confused and inactive.

The New Solution: The "Magic Derivative" (ACB1801)

This study introduces a new compound called ACB1801 (a derivative of a natural plant substance called Harmine). Think of ACB1801 not as a bomb, but as a Swiss Army Knife that performs three specific jobs to help the Anti-PD-1 key work.

1. The "Spotlight" Effect (Turning on the Lights)

The cancer cells are good at hiding. ACB1801 acts like a giant spotlight.

• How it works: It triggers a signaling pathway (called STAT1) inside the cancer cells. This signal tells the cancer cells to stop hiding.
• The Result: The cancer cells put up "Wanted Posters" on their surface (increasing MHC-I). Suddenly, the immune soldiers can clearly see the enemy.
• The Messenger: It also makes the cancer cells shout for help by releasing a chemical signal called CXCL10. This is like a flare gun that says, "Come here! The enemy is right here!" This attracts more immune soldiers (CD8+ T-cells) into the tumor.

2. The "Starvation" Effect (Cutting the Power)

Cancer cells are greedy; they eat sugar (glucose) at a massive rate to grow and to create a toxic environment that hurts the immune system.

• How it works: ACB1801 cuts the power lines to the cancer's sugar factory. It stops the cells from processing sugar efficiently.
• The Result: The cancer cells stop producing the toxic "fog" (lactate) that was confusing the immune army. The environment becomes cleaner and friendlier for the immune soldiers to fight.

3. The "Self-Destruct" Button (Inducing Ferroptosis)

This is the most creative part. Because the cancer cells are starving and their internal chemistry is messed up, they become fragile.

• How it works: ACB1801 removes the cancer's "rust-proofing" (antioxidants). Without this protection, the cells start to rust from the inside out.
• The Result: This is called Ferroptosis. It's like the castle walls starting to crumble and rust away on their own. The cancer cells literally explode from internal damage.

The Grand Strategy: The "One-Two Punch"

The study found that using ACB1801 alone is good, but using it together with the standard Anti-PD-1 therapy is a game-changer.

• Step 1: ACB1801 strips the camouflage, turns on the spotlight, and makes the cancer cells rust and starve.
• Step 2: The Anti-PD-1 therapy removes the "brakes" from the immune army.
• The Outcome: The immune army, now able to see the enemy and reach them, rushes in and destroys the tumor.

The Bottom Line

In the mouse models used in this study, this combination therapy shrank tumors significantly and helped the mice live much longer.

In simple terms: The researchers found a way to take a "cold" tumor (one the immune system ignores) and turn it into a "hot" tumor (one the immune system attacks). They did this by forcing the cancer to show its true face, starving it of sugar, and making it rust from the inside, all while helping the body's natural defenses do their job. This offers a huge hope for the 85% of colorectal cancer patients who currently don't respond to immunotherapy.

Technical Summary

1. Problem Statement

• Clinical Challenge: Microsatellite stable (MSS) colorectal cancer (CRC) accounts for approximately 80–85% of CRC cases. Unlike microsatellite instability-high (MSI-H) tumors, MSS tumors are typically "immunologically cold," characterized by low tumor mutational burden (TMB), poor antigen presentation, and a lack of tumor-infiltrating lymphocytes (TILs). Consequently, they are largely refractory to immune checkpoint blockade (ICB) therapies, such as anti-PD-1.
• Unmet Need: There is an urgent need for therapeutic strategies that can convert "cold" MSS tumors into "hot," immunoresponsive tumors to sensitize them to ICB.
• Hypothesis: The study investigates whether ACB1801, a synthetic derivative of the natural alkaloid harmine, can reprogram the tumor microenvironment (TME) and tumor cell metabolism to overcome anti-PD-1 resistance in MSS CRC.

2. Methodology

The study employed a multi-faceted approach combining in vivo mouse models, in vitro mechanistic studies, and transcriptomic profiling:

• In Vivo Model:
  • Used the CT26 syngeneic mouse model (BALB/c mice) to simulate MSS CRC.
  • Treatment Groups: Vehicle, ACB1801 alone, anti-PD-1 alone, and the combination (ACB1801 + anti-PD-1).
  • Endpoints: Tumor growth kinetics, survival rates, tumor weight, and immune profiling via flow cytometry.
• In Vitro Models:
  • Utilized mouse (CT26, MC38) and human (HT29) MSS CRC cell lines.
  • Assays: Cell viability (CellTiter-Glo), ferroptosis induction (GSH/GSSG ratio, ROS, lipid peroxidation), cytokine profiling (ELISA, Proteome Profiler), and cytotoxicity assays using OT-I CD8+ T cells.
• Molecular & Transcriptomic Analysis:
  • RNA-Seq: Performed on CD45+ (immune) and CD45- (tumor) cells isolated from tumors to identify pathway enrichment.
  • Mechanistic Validation: Western blotting (STAT1 phosphorylation), qRT-PCR (gene expression of glycolysis, ferroptosis, and MHC-I genes), and siRNA knockdown experiments (targeting STAT1 and NLRC5).
  • Metabolic Assays: Measurement of intracellular/extracellular glucose, lactate, and GSH/GSSG ratios.

3. Key Contributions & Mechanisms

The paper elucidates a dual mechanism by which ACB1801 sensitizes MSS CRC to anti-PD-1 therapy:

A. Immunogenic Reprogramming (STAT1/NLRC5/CXCL10 Axis)

• STAT1 Activation: ACB1801 induces phosphorylation of STAT1 at Tyr701 (pSTAT1) in tumor cells.
• Upregulation of MHC-I: Activated STAT1 upregulates NLRC5 (a master transcriptional regulator of MHC-I genes). This leads to increased expression of MHC-I molecules (H-2Kd in mice, HLA-A/B/C in humans) and antigen processing machinery (TAP1, TAP2, B2M).
• Chemokine Secretion: STAT1 activation drives the secretion of CXCL10, a chemokine that recruits CXCR3+ CD8+ T cells into the tumor.
• Result: Enhanced antigen presentation and T-cell infiltration transform the "cold" TME into a "hot" one.

B. Metabolic Reprogramming (Glycolysis/Ferroptosis Axis)

• Glycolysis Suppression: ACB1801 downregulates key glycolytic enzymes (HK2, LDHA, PFKL, ENO1) and transporters (GLUT1, SLC16A3), reducing intracellular glucose and lactate production. This alleviates the immunosuppressive acidic TME caused by lactate.
• Ferroptosis Induction: The drug suppresses ferroptosis inhibitors (SLC7A11, NRF2, GPX4, HSPA5) and drivers of lipid peroxidation. This creates a metabolic vulnerability where tumor cells become highly susceptible to ferroptotic cell death (iron-dependent lipid peroxidation).
• LCN2 Downregulation: ACB1801 reduces LCN2 secretion, which is known to promote Treg accumulation, thereby further reducing immunosuppression.

4. Key Results

• Therapeutic Efficacy:
  • Monotherapy with ACB1801 or anti-PD-1 showed minimal effect on tumor growth.
  • Combination Therapy: Significantly reduced tumor volume and weight, and markedly improved overall survival compared to controls.
• Immune Landscape Remodeling:
  • The combination group showed a significant increase in CD8+ T cell infiltration and a decrease in Regulatory T cells (Tregs), resulting in a high CD8+/Treg ratio.
  • Transcriptomic analysis of CD45+ cells confirmed enrichment of adaptive immunity, type II interferon signaling, and cytotoxicity pathways.
• Metabolic & Molecular Validation:
  • Glycolysis: ACB1801 treatment significantly lowered intracellular glucose and lactate levels in both mouse and human cells.
  • Ferroptosis: Treatment increased ROS and lipid peroxidation. Crucially, co-treatment with the ferroptosis inhibitor Ferrostatin-1 completely abrogated ACB1801-induced cell death, confirming ferroptosis as the mechanism of direct tumor killing.
  • MHC-I & CXCL10: ACB1801 increased surface MHC-I expression and CXCL10 secretion. Knockdown of STAT1 or NLRC5 abolished these effects, confirming the dependency on this signaling axis.
  • Cytotoxicity: ACB1801-treated tumor cells were more effectively killed by OT-I CD8+ T cells in an antigen-dependent manner.

5. Significance and Conclusion

• Overcoming Resistance: This study provides a robust preclinical rationale for using harmine derivatives to overcome resistance to ICB in the majority of CRC patients (MSS) who currently lack effective immunotherapies.
• Dual-Action Strategy: The novelty lies in the simultaneous targeting of two distinct vulnerabilities:
  1. Immune Evasion: By boosting antigen presentation (MHC-I) and T-cell recruitment (CXCL10) via STAT1/NLRC5.
  2. Metabolic Vulnerability: By starving the tumor of glycolytic support and forcing it into ferroptosis, thereby reducing the immunosuppressive lactate burden and directly killing tumor cells.
• Clinical Translation: The findings suggest that combining ACB1801 with anti-PD-1 could convert "cold" MSS tumors into "hot" tumors, offering a promising therapeutic strategy for a large patient population currently excluded from ICB benefits. The study highlights the potential of targeting metabolic pathways (glycolysis/ferroptosis) as a potent adjuvant to immunotherapy.